10月24日 - ** 制药商Kura Oncology KURA.O股价盘前上涨5.6%至9.61美元
** 该公司在为急性髓性白血病晚期试验的首例患者用药后获得了3000万美元的里程碑付款(AML)，这是一种快速增长的血癌。
** 该试验测试了口服实验药物齐夫替尼（ziftomenib）和化疗对新诊断出的NPM1或KMT2A突变急性髓性白血病患者的疗效--KURA
** 这些突变是急性髓细胞白血病中发现的基因变化；NPM1与较好的初始化疗反应有关，而KMT2A与侵袭性疾病和较高的复发风险有关
** 公司称，试验已于上月宣布启动；Ziftomenib是一种每日一次的口服治疗药物
** 美国癌症协会称，美国每年约有 22,000 人罹患这种疾病
** 截至上次收盘，股价年累计上涨约 4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.